Interviews with the world’s key opinion leaders in cancer

TagMetastatic castration-resistant refractory prostate cancer

Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

February 6, 2014

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099...

TagMetastatic castration-resistant refractory prostate cancer

Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

Menu